Across TCGA pan-cancer cohorts, ZXDA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZXDA data layer compared with 25 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZXDA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZXDA expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.
HNSC, CHOL, and STAD are the cancer types where ZXDA Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.